We describe the case of a 39-year-old man who experienced a ventricular fibrillation storm related to a prominent J wave in the inferior and lateral electrocardiographic leads on the day after gastrostomy. The J wave slowly decreased after amiodarone therapy (400 mg/day) was started, and ventricular fibrillation disappeared.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/j.1540-8159.2006.00481.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Circumstances in a young German cohort with sudden cardiac arrest: systematic insights and implications.
Clin Res Cardiol
January 2025
University Hospital St Josef Hospital, Cardiology and Rhythmology, Ruhr University, Bochum, Germany.
Introduction: Data on circumstances of sudden cardiac arrest (SCA) in Germany are limited. The present study aimed to investigate systematically the current pre- and in-hospital circumstances of a SCA cohort at young age (65 years or younger) in Germany.
Methods: In the period from 2010 to 2021, we enrolled 191 consecutive patients with SCA at a university hospital in the Ruhr area, Germany.
Prediction of reduced left ventricular ejection fraction using atrial fibrillation or flutter electrocardiograms: A machine-learning study.
Digit Health
January 2025
Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea.
Objective: Although the evaluation of left ventricular ejection fraction (LVEF) in patients with atrial fibrillation (AF) or atrial flutter (AFL) is crucial for appropriate medical management, the prediction of reduced LVEF (<50%) with AF/AFL electrocardiograms (ECGs) lacks evidence. This study aimed to investigate deep-learning approaches to predict reduced LVEF (<50%) in patients with AF/AFL ECGs and easily obtainable clinical information.
Methods: Patients with 12-lead ECGs of AF/AFL and echocardiography were divided into those with LVEF <50% and ≥50%.
A comprehensive review of the efficacy and safety of ertugliflozin.
Expert Opin Drug Metab Toxicol
January 2025
The First Affiliated Hospital, Hunan Provincial Clinical Medical Research Center for Drug Evaluation of Major Chronic Diseases, Hengyang Medical School, University of South China, Hengyang, Hunan, China.
Introduction: Ertugliflozin is the fourth sodium-glucose co-transporter (SGLT2) inhibitor approved by the US FDA in 2017 for the treatment of type 2 diabetes mellitus.
Areas Covered: The main purpose of this review is to evaluate the clinical efficacy and safety of ertugliflozin. We conducted a search of relevant literature on ertugliflozin in the PubMed and Web of Science databases up to 22 October 2024.
Left atrial functional impairment as a predictor of atrial fibrillation: insights from cardiac CT.
Eur Radiol
January 2025
Rappaport Faculty of Medicine, Technion - Israel Institute of Technology, Haifa, 3525422, Israel.
Objectives: A strong association exists between left atrial (LA) structural remodeling and the development of atrial fibrillation (AF). The role of LA function in AF prediction remains unclear. We studied the relationship between LA function and incident AF using cardiac CT.
View Article and Find Full Text PDFCoexistence of cardiac sarcoidosis and arrhythmogenic cardiomyopathy-associated genetic variants: a multicentre case-control study.
Heart
January 2025
Department of Cardiology, University Hospital Zurich, Zurich, Switzerland
Background: Cardiac sarcoidosis (CS) is a chronic inflammatory disease characterised by non-caseating granulomas, while arrhythmogenic cardiomyopathy (ACM) is a genetic condition mainly affecting desmosomal proteins. The coexistence of CS and genetic variants associated with ACM is not well understood, creating challenges in diagnosis and management. This study aimed to describe the clinical, imaging and genetic features of patients with both conditions.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!